AACR Annual Meeting 2017: If You Can’t Drug It, Degrade It – A Protein Degradation Technology to Tackle Undruggable Oncoproteins

Finding a way to therapeutically target the so-called “undruggable” cancer proteins has long been a holy grail of researchers in the field of oncology drug development.

Read More

Overcoming Drug Resistance: The EGFR Enigma

Currently, anti-EGFR therapies are approved by the U.S. Food and Drug Administration for the treatment of non-small cell lung cancer, squamous cell carcinoma of the head and neck, pancreatic cancer, and colorectal cancer. Most patients receiving anti-EGFR therapies benefit from the treatment, but the challenge they face, as do patients receiving most other targeted therapies, is that their tumors ultimately develop drug resistance. So efforts are underway to develop newer anti-EGFR therapies that can circumvent resistance to existing EGFR inhibitors.

Read More

Q&A With Lee Helman, MD, on New Cancer Targets and Therapeutics

The National Cancer Institute’s Lee Helman, MD, co-chair of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, discusses what to expect this year, and peers into the future of targeted cancer therapies and immunotherapy.

Read More